These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 5101783)

  • 1. Etiology of hyperparathyroidism and bone disease during chronic hemodialysis. I. Association of bone disease with potentially etiologic factors.
    Fournier AE; Johnson WJ; Taves DR; Beabout JW; Arnaud CD; Goldsmith RS
    J Clin Invest; 1971 Mar; 50(3):592-8. PubMed ID: 5101783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etiology of hyperparathyroidism and bone disease during chronic hemodialysis. II. Factors affecting serum immunoreactive parathyroid hormone.
    Fournier AE; Arnaud CD; Johnson WJ; Taylor WF; Goldsmith RS
    J Clin Invest; 1971 Mar; 50(3):599-605. PubMed ID: 5545122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of dialysate calcium concentration in hemodialysis.
    Toussaint N; Cooney P; Kerr PG
    Hemodial Int; 2006 Oct; 10(4):326-37. PubMed ID: 17014507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperparathyroidism in chronic renal failure and dialysis osteodystrophy.
    O'Riordan JL; Page J; Kerr DN; Walls J; Moorhead J; Crockett RE; Franz H; Ritz E
    Q J Med; 1970 Jul; 39(155):359-76. PubMed ID: 5478506
    [No Abstract]   [Full Text] [Related]  

  • 6. Azotemic osteodystrophy - indications for intervention.
    Ritz E
    Prog Biochem Pharmacol; 1980; 17():251-8. PubMed ID: 7208504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between different dialysate calcium concentrations in nocturnal hemodialysis.
    Toussaint ND; Polkinghorne KR; Kerr PG; Somerville CA; Agar JW
    Hemodial Int; 2007 Apr; 11(2):217-24. PubMed ID: 17403174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium.
    Spasovski G; Gelev S; Masin-Spasovska J; Selim G; Sikole A; Vanholder R
    Bone; 2007 Oct; 41(4):698-703. PubMed ID: 17643363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ratio of cyclase activating and cyclase inactive parathormone (CAP/CIP) in dialysis patients: correlations with other markers of bone disease.
    Grzegorzewska AE; Młot M
    Rocz Akad Med Bialymst; 2004; 49():190-2. PubMed ID: 15631341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma calcium fraction dynamics in uremic patients undergoing hemodialysis.
    Asad SN; Olmer AJ; Letteri JM
    Miner Electrolyte Metab; 1984; 10(5):333-6. PubMed ID: 6493162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of conjunctival and corneal calcification with vascular calcification in dialysis patients.
    Seyahi N; Altiparmak MR; Kahveci A; Yetik H; Kanberoglu K; Serdengecti K; Ataman R; Erek E
    Am J Kidney Dis; 2005 Mar; 45(3):550-6. PubMed ID: 15754277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chronic kidney disease (CKD) and bone. Management of chronic kidney disease-mineral and bone disorder in peritoneal dialysis patients].
    Yaginuma T; Yamamoto H
    Clin Calcium; 2009 Apr; 19(4):508-13. PubMed ID: 19329829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
    Nasri H; Baradaran A; Naderi AS
    Acta Med Austriaca; 2004 Aug; 31(3):67-72. PubMed ID: 15515479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of lowering dialysate calcium concentration on mineral metabolism and parathyroid hormone secretion: a multicentric study.
    Lezaic V; Pejanovic S; Kostic S; Pljesa S; Dimkovic N; Komadina L; Jovanovic D; Marinkovic J; Djukanovic L
    Ther Apher Dial; 2007 Apr; 11(2):121-30. PubMed ID: 17381533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is secondary hyperparathyroidism an important etiologic factor in the anemia of chronic renal failure?
    Wainer E; Wittenberg C; Hochman B; Olah AJ; Rosenfeld JB; Boner G
    Isr J Med Sci; 1982 Feb; 18(2):249-54. PubMed ID: 7068355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropeptide Y and markers of osteoblast activity in dialysis patients: a cross-sectional study.
    Panuccio V; Cutrupi S; Pizzini P; Mallamaci F; Tripepi G; Zoccali C
    Am J Kidney Dis; 2007 Dec; 50(6):1001-8. PubMed ID: 18037100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between C-reactive protein and biomarkers of bone and mineral metabolism in chronic hemodialysis patients: a cross-sectional study.
    Lee CT; Tsai YC; Ng HY; Su Y; Lee WC; Lee LC; Chiou TT; Liao SC; Hsu KT
    J Ren Nutr; 2009 May; 19(3):220-7. PubMed ID: 19243976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcitropic hormonal status in north Indian patients with end-stage renal disease.
    Singh AK; Avula S; Kher V; Rao DS; Mithal A
    Natl Med J India; 1999; 12(5):202-7. PubMed ID: 10612998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Selected parameters of bone metabolism in hemodialyzed and peritoneally dialyzed patients].
    Małyszko J; Zbroch E; Wołczyński S; Myśliwiec M
    Przegl Lek; 2000; 57(12):711-3. PubMed ID: 11398592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different routes bridging calcium in Japanese hemodialysis patients.
    Hamano T; Fujii N; Ito T; Imai E
    Ther Apher Dial; 2005 Feb; 9(1):32-8. PubMed ID: 15828903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.